Global Progesterone Market Size study & Forecast, by Type (Natural Progesterone, Synthetic Progesterone), By Mode of Delivery (Injectable, Suspended Form, Oral), By Application (Regulation of the Menstrual Cycle, Dysfunctional Uterine Bleeding, Endometria

Global Progesterone Market Size study & Forecast, by Type (Natural Progesterone, Synthetic Progesterone), By Mode of Delivery (Injectable, Suspended Form, Oral), By Application (Regulation of the Menstrual Cycle, Dysfunctional Uterine Bleeding, Endometrial Cancer, Contraception, Hyperplastic Precursor Lesions) and Regional Analysis, 2023-2030

Global Progesterone Market is valued at approximately USD 1157.2 million in 2022 and is anticipated to grow with a healthy growth rate of more than 13.3% over the forecast period 2023-2030. Progesterone is a female hormone that is primarily produced by the ovaries after ovulation. It plays a crucial role in preparing the uterus for pregnancy and maintaining a healthy pregnancy. Progesterone also helps regulate the menstrual cycle and is involved in the development of breast tissue. It can also be used as a medication to treat various conditions, such as irregular periods, infertility, and menopausal symptoms. It is often prescribed as part of hormone replacement therapy for menopausal women. The Progesterone market is expanding because of factors such increasing incidence of endometrial cancer and growing cases of female infertility and breast cancer.

During pregnancy, progesterone levels rise significantly and help to prevent premature contractions of the uterus. After menopause, progesterone production declines, along with estrogen, which can lead to symptoms such as hot flashes, vaginal dryness, and bone loss. Its prevalence has progressively increased during the last few decades. According to the American Cancer Society, in 2023 about 66,200 new cases of cancer of the body of the uterus will be diagnosed. Furthermore, around 13,030 women will die from cancers of the uterine body in the United States. In addition, about 13,960 new cases of invasive cervical cancer will be diagnosed and 4,310 women will die from cervical cancer during the same year. Another important component driving space is increasing cases of female infertility and breast cancer. According to World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. In addition, as per the American Society of Clinical Oncology in 2023, an estimated 297,790 women in the United States will be diagnosed with invasive breast cancer, and 55,720 women will be diagnosed with non-invasive breast cancer. Also, advancements in formulation and technological advancements in the medical industry would create a lucrative growth prospectus for the market over the forecast period. However, lack of awareness regarding the availability of hormone therapy stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Progesterone Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing number of breast cancer in the region. According to Breastcancer.org, In 2022, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive breast cancer. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as rising target populations, and active participation of government and nonprofit organizations in the market space.

Major market players included in this report are:
Estrellas Life Sciences Private Ltd
Bionpharma Inc.,
Sofgen Pharmaceuticals,
Teva Pharmaceuticals Industries Ltd
Virtus Pharmaceuticals Llc,
Blubell Pharma Group Company, Aquatic Remedies Pvt. Ltd.,
Intas Pharmaceuticals Ltd.,
Shanghai Yijing Industrial Co ltd
Wuhan Honor Bio-Pharm Co., Ltd

Recent Developments in the Market:
In November 2020, Prestige BioPharma Ltd. and Abic Marketing Ltd., a subsidiary of Teva Pharmaceutical Industries Ltd., signed an exclusive cooperation and supply agreement for the commercialization of Prestige BioPharma's Trastuzumab biosimilar in Israel.

Global Progesterone Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Type, Mode of Delivery, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type
Natural Progesterone
Synthetic Progesterone

By Mode of Delivery
Injectable
Suspended Form
Oral

By Application
Regulation of the Menstrual Cycle
Dysfunctional Uterine Bleeding
Endometrial Cancer
Contraception
Hyperplastic Precursor Lesions

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Estrellas Life Sciences Private Ltd
Bionpharma Inc.,
Sofgen Pharmaceuticals,
Teva Pharmaceuticals Industries Ltd
Virtus Pharmaceuticals Llc,
Blubell Pharma Group Company, Aquatic Remedies Pvt. Ltd.,
Intas Pharmaceuticals Ltd.,
Shanghai Yijing Industrial Co ltd
Wuhan Honor Bio-Pharm Co., Ltd

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.